01541 PE Ratio & Valuation,Is 01541 Overvalued — Intellectia
01541 Relative Valuation
01541's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, 01541 is overvalued; if below, it's undervalued.
Historical Valuation
IMMUNEONCO-B(01541) is now in theFairzone, suggesting that its currentforward PSratio of14.03is consideredFairlycompared with the five-year average of-13.68.The fair price ofIMMUNEONCO-B(01541)is between--to--according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：6.21
Fair
-8.11
PE
1Y
3Y
5Y
Trailing
Forward
-7.69
EV/EBITDA
IMMUNEONCO-B. (01541) has a current EV/EBITDA of -7.69. The 5-year average EV/EBITDA is -12.59. The thresholds are as follows: Strongly Undervalued below -26.74, Undervalued between -26.74 and -19.66, Fairly Valued between -5.51 and -19.66, Overvalued between -5.51 and 1.56, and Strongly Overvalued above 1.56. The current Forward EV/EBITDA of -7.69 falls within the Historic Trend Line -Fairly Valued range.
-7.11
EV/EBIT
IMMUNEONCO-B. (01541) has a current EV/EBIT of -7.11. The 5-year average EV/EBIT is -12.03. The thresholds are as follows: Strongly Undervalued below -25.82, Undervalued between -25.82 and -18.93, Fairly Valued between -5.13 and -18.93, Overvalued between -5.13 and 1.77, and Strongly Overvalued above 1.77. The current Forward EV/EBIT of -7.11 falls within the Historic Trend Line -Fairly Valued range.
14.03
PS
IMMUNEONCO-B. (01541) has a current PS of 14.03. The 5-year average PS is 4483.75. The thresholds are as follows: Strongly Undervalued below -4754.35, Undervalued between -4754.35 and -135.30, Fairly Valued between 9102.80 and -135.30, Overvalued between 9102.80 and 13721.85, and Strongly Overvalued above 13721.85. The current Forward PS of 14.03 falls within the Historic Trend Line -Fairly Valued range.
-15.43
P/OCF
IMMUNEONCO-B. (01541) has a current P/OCF of -15.43. The 5-year average P/OCF is -8.88. The thresholds are as follows: Strongly Undervalued below -32.14, Undervalued between -32.14 and -20.51, Fairly Valued between 2.75 and -20.51, Overvalued between 2.75 and 14.38, and Strongly Overvalued above 14.38. The current Forward P/OCF of -15.43 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
IMMUNEONCO-B. (01541) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
IMMUNEONCO-B (01541) has a current Price-to-Book (P/B) ratio of 4.31. Compared to its 3-year average P/B ratio of 7.16 , the current P/B ratio is approximately -39.80% higher. Relative to its 5-year average P/B ratio of 7.16, the current P/B ratio is about -39.80% higher. IMMUNEONCO-B (01541) has a Forward Free Cash Flow (FCF) yield of approximately -5.54%. Compared to its 3-year average FCF yield of -6.41%, the current FCF yield is approximately -13.59% lower. Relative to its 5-year average FCF yield of -6.41% , the current FCF yield is about -13.59% lower.
4.31
P/B
Median3y
7.16
Median5y
7.16
-5.54
FCF Yield
Median3y
-6.41
Median5y
-6.41
Performance Decomposition
1Y
3Y
5Y
Market capitalization of 01541 increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of 01541 in the past 1 year is driven by Unknown.
Is IMMUNEONCO-B (01541) currently overvalued or undervalued?
IMMUNEONCO-B(01541)is now in theFairzone, suggesting that its currentforward PSratio of 14.03is consideredFairlycompared with the five-year average of-13.68.The fair price of IMMUNEONCO-B(01541)is betweentoaccording to relative valuation methord.
What is IMMUNEONCO-B (01541) fair value?
01541's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of IMMUNEONCO-B (01541) is between to according to relative valuation methord.
How does 01541's valuation metrics compare to the industry average?
The average P/S ratio for 01541's competitors is , providing a benchmark for relative valuation. IMMUNEONCO-B Corp (01541) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for IMMUNEONCO-B (01541) as of Dec 16 2025?
As of Dec 16 2025, IMMUNEONCO-B (01541) has a P/B ratio of 4.31. This indicates that the market values 01541 at 4.31 times its book value.
What is the current FCF Yield for IMMUNEONCO-B (01541) as of Dec 16 2025?
As of Dec 16 2025, IMMUNEONCO-B (01541) has a FCF Yield of -5.54%. This means that for every dollar of IMMUNEONCO-B’s market capitalization, the company generates -5.54 cents in free cash flow.
What is the current Forward P/E ratio for IMMUNEONCO-B (01541) as of Dec 16 2025?
As of Dec 16 2025, IMMUNEONCO-B (01541) has a Forward P/E ratio of -8.11. This means the market is willing to pay $-8.11 for every dollar of IMMUNEONCO-B’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for IMMUNEONCO-B (01541) as of Dec 16 2025?
As of Dec 16 2025, IMMUNEONCO-B (01541) has a Forward P/S ratio of 14.03. This means the market is valuing 01541 at $14.03 for every dollar of expected revenue over the next 12 months.
